Skip to main content

Table 3 Adverse events reported by ≥ 5% of the patients of any study group (safety population)

From: Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study

Preferred term (MedDra)EVO 2.5 mg (N = 35)EVO 5 mg (N = 36)EVO 10 mg (N = 36)SITA 100 mg (N = 39)
Headache0 (0.0)5 (13.9)1 (2.8)1 (2.6)
GGT elevated4 (11.4)0 (0.0)0 (0.0)0 (0.0)
Hypertension3 (8.6)2 (5.6)0 (0.0)3 (7.7)
Diarrhea3 (8.6)1 (2.8)1 (2.8)2 (5.1)
Flu-like symptoms1 (2.9)2 (5.6)3 (8.3)3 (7.7)
Urinary tract infection1 (2.9)2 (5.6)3 (8.3)2 (5.1)
T2DM with inadequate control2 (5.7)1 (2.8)0 (0.0)1 (2.6)
Dizziness0 (0.0)1 (2.8)2 (5.6)1 (2.6)
Eosinophilia0 (0.0)2 (5.6)0 (0.0)1 (2.6)
Abdominal pain1 (2.9)1 (2.8)2 (5.6)0 (0.0)
Dyslipidemia1 (2.9)0 (0.0)2 (5.6)0 (0.0)
Back pain0 (0.0)1 (2.8)2 (5.6)0 (0.0)
Upper airway infection1 (2.9)2 (5.6)0 (0.0)0 (0.0)
Dyspepsia0 (0.0)0 (0.0)2 (5.6)0 (0.0)
Nausea1 (2.9)1 (2.8)1 (2.8)2 (5.1)
Hyperglycemia1 (2.9)0 (0.0)0 (0.0)2 (5.1)
  1. EVO evogliptin, GGT gamma-glutamyl transferase, T2DM type 2 diabetes mellitus